Cidara Therapeutics Inc.

Quick facts

Phase 2 pipeline

• CD101 · Infectious Disease
  CD101 is a recombinant human monoclonal antibody targeting beta-glucan.

Phase 1 pipeline

• CD101 IV
• Fluzone HD influenza vaccine

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Cidara Therapeutics Inc. portfolio CI brief
• Cidara Therapeutics Inc. pipeline updates RSS